23andMe, the leading consumer genetics and research company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. Our Therapeutics team in South San Francisco leverages this data to discover and develop new treatments that can offer significant benefits for patients with serious, unmet medical needs.
This dedicated research and drug development group identifies novel targets using 23andMe's genetic database and performs preclinical research to advance programs towards clinical development. We currently have programs across several therapeutic areas, including but not limited to oncology, respiratory, and cardiovascular diseases. More information about our Therapeutics team is available at https://therapeutics.23andme.com/.
We are seeking a highly motivated immunohistochemistry / image analysis researcher to join our Biomarker Translation team where you will have the unique opportunity to influence and make a substantial impact on our programs across multiple disease areas and help bring effective therapies to patients in need. In close collaboration with biologists, geneticists, immunologists, and in vivo scientists, you will design and perform immunohistochemistry and in situ hybridization assays in support of target validation, preclinical efficacy, and translational research. You will be responsible for designing and implementing, in-house and at CROs, single-plex and multiplexed immunohistochemistry (IHC), immunofluorescence (IF), and in situ hybridization (ISH) assays and present your data at team meetings. This is a unique opportunity for a tissue-based scientist who wants to learn and grow in a stimulating and supporting environment.
What you'll do
- Develop IHC/IF/ISH assays on automated autostainer
- Perform WB and qRTPCR, QC and integrate these results
- Perform quality control and troubleshooting on IHC/ISH runs
- Apply these assays in support of efficacy, mechanistic, target discovery, and safety studies
- Be the subject matter expert to design, implement and analyze single-plex and multiplex tissue- based assays, presenting your data to team and larger discovery audience
- Support and monitor CROs and in vivo colleagues in the design and execution of pathology assays, including tissue collection, tissue processing, and IHC/immunofluorescence/in situ hybridization
- Design effective workflows to ensure timely and consistent delivery
- Help to track/maintain inventory of reagents for IHC/ISH assays
- Assist with the digitization of slides and conduct image analysis on the digital slides as needed
- Evaluate new technologies and help with resource planning
- Maintain compliance with all company policies and procedures
What you’ll bring
- 2-5 years of relevant work experience in tissue-based pathology fields ideally in Biotechnology or Pharmaceuticals
- Bachelor or graduate degree in molecular biology, cancer biology, immunology, pathology or related fields
- Advanced skills in immunohistochemistry and in situ hybridization method development, optimization and troubleshooting, including multiplexing
- Expertise in digital pathology image analysis platforms (e.g. Visiopharm, HALO or similar systems)
- Experience with software applications for data management and analysis, such as Spotfire, Prism, JMP and/or Excel
- Excellent written and verbal communication skills
- Critical thinking with high degree of innovative and analytical skills
- Ability to work efficiently and independently, prioritize workflows, meet deadlines and balance competing priorities
- Passion for working in a highly collaborative team environment
- Possesses a sense of urgency, scientific rigor and integrity, and empathy for the patient
- Working knowledge of regulatory requirements (e.g., FDA, GLP, CLIA, CAP, etc.)
- Experience in companion diagnostics
Note: Job title will be commensurate with experience and academic credentials.
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand, and benefit from the human genome. The company was named by Glassdoor as one of the Best Places to Work in 2019, MIT Technology Review to its “50 Smartest Companies, 2017” list, and named one of Fast Company’s “25 Brands That Matter Now, 2017”. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. More information is available at www.23andMe.com.
At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws. If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at email@example.com. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.
Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.